[207 Pages Report] Sales in the global Radiation-Induced Myelosuppression Treatment Market are slated to total US$ 2.9 Billion in 2022. Expanding at a steady 3.1% CAGR, the market valuation is projected to top US$ 3.5 Billion in 2028.
| Attribute | Details |
|---|---|
| Radiation-Induced Myelosuppression Treatment Estimated Market Size 2022 | US$ 2.9 Billion |
| Radiation-Induced Myelosuppression Treatment Market Value-based CAGR (2022 to 2028) | 3.1% |
| Radiation-Induced Myelosuppression Treatment Market Projected Size in 2028 | US$ 3.5 Billion |
Increasing incidence of cancer worldwide is underpinning the need for advanced cancer treatment options and therapies. Early diagnosis and the availability of radiotherapy and chemotherapy are expected to fuel sales in the market through 2031.
In addition to this, the introduction of adjuvant therapy for cancer is playing a vital role in reducing the death rate of cancer, improving disease management, and the overall quality of life in cancer patients. As per Future Market Insights, the market is projected to expand on the back of the aforementioned factors over the forecast period.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Particulars | Details |
|---|---|
| H1, 2021 | 3.42% |
| H1, 2022 Projected | 3.12% |
| H1, 2022 Outlook | 2.62% |
| BPS Change - H1, 2022 (O) - H1, 2022 (P) | (-) 50 ↓ |
| BPS Change - H1, 2022 (O) - H1, 2021 | (-) 80 ↓ |
Future Market Insights presents a comparative analysis about the market growth rates and development prospects in the global market. According to FMI analysis, the radiation-induced myelosuppression treatment market is expected to drop by 80 Basis Point Share (BPS) in H1- 2022 compared to H1-2021.
However, BPS change of only 50 BPS was observed when comparing H1-2022 Outlook and H1-2022 Projected growth. Key reason for this dip in BPS is attributed to the factor such as stringent government regulations and approval process for pipeline products, which impacted the growth of the market.
However, some positive factors which will influence the market growth in future include new developments and introduction of novel therapeutics for treatment of radiation induced myelosuppression. For instance, on Feb 2021, FDA approved trilaciclib (Cosela, G1 Therapeutics) for lowering the rate of chemotherapy-induced myelosuppression (CIM) in adult patients suffering from extensive-stage small-cell lung cancer (ES-SCLC).
Demand in the radiation-induced myelosuppression treatment market is projected to increase at a 3.1% CAGR, in comparison to the 3.4% CAGR registered between 2013 to 2031.
The availability of various growth factors and favorable treatment guidelines have made the management of neutropenia easier. However, thrombocytopenia and anemia are still posing a burden on the healthcare system.
Thrombocytopenia can be managed with the help of available growth factors, but most of them are off-label. The management of anemia remains a challenge for cancer patients who receive radiation therapy for cancer treatment.
Due to changes in reimbursement and labeling of medications for anemia, the use of off-label indication erythropoietin-stimulating agents has decreased to an extent. This has resulted in growing need for blood transfusion, which is associated with various risk factors.
This, in turn, is underscoring the significance of myelosuppression treatment therapeutics and drugs, which is expected to boost the market over the assessment period.
Anemia is a common consequence of chronic kidney diseases (CKD) and radiation-induced myelosuppression. Due to the insufficiency of erythropoietin synthesis, patients suffer from anemia. However, the combination of erythropoiesis-stimulating agents (ESA) and iron has become a standard treatment for anemia.
ESAs effectively increase the hemoglobin (Hb) levels in patients. However, their use has been associated with increased cardiovascular risk, especially due to high dose intake in inflamed and hyporesponsive patients.
Iron deficiency is another consequence of anemia. This has resulted in the introduction of intravenous iron therapy which is beneficial for anemic patients, CKD patients, and patients dealing with heart failure.
A new class of drugs, namely prolyl hydroxylase domain (PHD) inhibitors is now available for the treatment of anemia. These drugs effectively stimulate the synthesis of endogenous erythropoietin and increase iron availability.
In addition to this, in February, the U.S. Food and Drug Administration (FDA) approved Cosela (Trilaciclib) as the first line of treatment in its class to reduce the frequency of bone marrow suppression in adults, which is caused by chemotherapy for the extensive stage.
Such developments are expected to provide impetus to the growth of the market over the assessment period, opines FMI.
Principal Consultant
“High Prevalence of Chemotherapy Induced Myelosuppression Will Spur Demand in the U.S.”
The U.S. is expected to dominate the North America radiation-induced myelosuppression treatment market owing to growing incidence of cancer, chronic kidney diseases (CKD), and patients dealing with heart failure.
The presence of leading market players and fast-tracked approvals by the FDA are expected to augment the growth of the U.S. market. In addition to this, the U.S. is home to a vast healthcare sector, which is expected to provide opportunities for growth to market players over the assessment period.
“Healthcare Providers are Prescribing Myelosuppressive Chemotherapy Drugs To improve Bone Marrow Function”
China is expected to account for a lion’s share of the East Asia radiation-induced myelosuppression treatment market. Increasing geriatric population in the country, along with high incidence of cancer and heart failure are spurring the demand for myelosuppression treatment drugs.
Further, increasing research and development activities for the development of iron deficiency treatment is expected to augment the growth of the market. Iron deficiency is a consequence of anemia caused by chemotherapy radiation.
Growing preference for erythropoiesis-stimulating agents (ESAs) for iron deficiency in the country is anticipated to boost the market in the forthcoming years.
“Surging Trend of Medical Tourism Will Boost Sales of Myelosuppression Chemotherapy Drugs”
The U.K. is expected to emerge as a lucrative pocket in the Europe radiation-induced myelosuppression treatment market owing to the influx of medical tourists in the country, along with the availability of superior healthcare facilities.
Increasing adoption of technologically advanced medical equipment for the treatment of various chronic disorders such and cancer and kidney failure in the country is expected to augment the growth of the market in the forthcoming years.
Further, rising awareness regarding adjuvant treatment for cancer in the U.K. will continue boosting the market over the assessment period.
“Surging Incidence of Neutropenia to Drive Preference for Myelosuppression Treatment Regimen”
Based on indication, sales in the neutropenia segment are projected to account for 43.3% of the total market share in 2022. Neutropenia is a condition where an individual deals with abnormally low counts of white blood cells.
Bone marrow malfunction caused by chemotherapy radiations is a chief factor driving sales in this segment. Lack of white blood cells in patients weakens the immune system and their ability to fight infections, which makes it imperative to seek treatment for the same.
Owing to the aforementioned factors, sales in this segment are projected to increase at a considerable pace over the assessment period.
“Rising Awareness Regarding New Erythropoietin Stimulating Agents Will Bolster Sales”
In terms of drug class, demand in the erythropoietin stimulating agents (ESA) segment is projected to remain high over the assessment period. ESAs effectively improve the efficacy of iron therapy in anemic patients after chemotherapy radiations, which is expected to continue pushing sales in the market.
Besides this, growing preference for intravenous iron therapy with a combination of ESAs is expected to complement the growth of the market in the forthcoming years. The combination of ESAs and IV iron therapy improve the red blood cells count as compared to other treatment using ESAs alone.
“Sales of Myelosuppression Chemotherapy Drugs to Remain High Via Hospital Pharmacies”
Based on the sales channel, sales in the hospital pharmacies segment are projected to increase at a considerable pace owing to the wide availability of therapeutic drugs in these shops. However, high convenience and timely delivery offered by online pharmacies will place them as a lucrative segment over the assessment period.
“Oral Route of Administration for Myelosuppression Chemotherapy Medication to Gain Traction”
In terms of route of administration, the oral route is expected to be preferred by both healthcare professionals and patients owing to ease of administration and high efficacy. Growing preference for non-invasive treatment options will also provide impetus to sales in this segment.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Leading players operating in the global radiation-induced myelosuppression treatment market are investing in research and development to improve lines of treatment for myelosuppression treatment. In addition to this, players are investing in mergers and acquisitions to strengthen their distribution channels.
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2028 |
| Historical Data Available for | 2013 to 2021 |
| Market Analysis | Units for Volume and US$ Million for Value |
| Key Regions Covered | North America; Latin America; Europe; East Asia; South Asia; Oceania, and MEA |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Nordic, Russia, Poland, China, India, Thailand, Indonesia, Australia and New Zealand, Japan, GCC countries, North Africa, South Africa, others. |
| Key Market Segments Covered | Indication, Drug Class, Route of Administration, Distribution Channel, and Region |
| Key Companies Profiled | Amgen Inc.; Novartis AG; Teva Pharmaceutical Industries Ltd; Mylan N.V.; Pfizer Inc.; Janssen Global Services, LLC (Johnson & Johnson); Partner Therapeutics, Inc.; Mission Pharmacal Company; Myelo Therapeutics GmbH; Pluristem Therapeutics Inc. |
| Pricing | Available upon Request |
Indication:
Drug Class:
Route of Administration:
Distribution Channel:
Region
The global radiation-induced myelosuppression treatment market is expected to reach a valuation of US$ 2.9 Bn in 2022.
The global Radiation-induced myelosuppression treatment market grew at a 3.4% CAGR between 2013 and 2021.
Increasing preference for non-invasive drug administration, along with the introduction of intravenous iron therapy are key trends driving radiation-induced myelosuppression treatment sales.
North America is projected to account for a dominant share of the global radiation-induced myelosuppression treatment market share during the forecast period.
The radiation-induced myelosuppression treatment market in Europe is anticipated to expand at a considerable pace over the assessment period.
1. Executive Summary 1.1. Market Overview 1.2. Market Analysis 1.3. FMI Analysis and Recommendations 1.4. Wheel of Fortune 2. Market Introduction 2.1. Market Taxonomy 2.2. Market Definition 2.3. Inclusion and Exclusions 3. Radiation Induced Myelosuppression Treatment Market Opportunity Analysis 3.1. Macro-Economic Factors 3.2. Opportunity Analysis 4. Market Background 4.1. Radiation Induced Myelosuppression Treatment Market Evolution 4.2. Market Dynamics 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Trends 5. Macroeconomic Assumptions 6. Global Economic Outlook 6.1. Gross Domestic Product by Region & Country, 2016 – 2021 7. Key Inclusions 7.1. Key Regulations 7.2. Pipeline Assessment 7.3. Patient Treatment Regimen/Patient Journey 8. Global Market Analysis 2013–2021 and Forecast 2022–2028 8.1. Market Value Share Analysis 8.2. Y-o-Y Growth Analysis 8.3. Absolute $ Opportunity 9. North America Radiation Induced Myelosuppression Treatment Market Analysis 2013–2021 and Forecast 2022–2028 9.1. Introduction 9.2. Historical Market Size (US$ Mn) Analysis By Country, 2013–2021 9.2.1. U.S. 9.2.2. Canada 9.3. Market Size (US$ Mn) Forecast By Country, 2022–2028 9.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013–2021 9.4.1. Growth Factors 9.4.1.1. Granulocyte Colony-Stimulating Factor 9.4.1.2. Thrombopoietin Receptor Agonists 9.4.2. Erythropoietin-stimulating Agents 9.4.3. Thrombopoietic Agents 9.4.4. Iron supplementation 9.4.5. Others 9.5. Market Size (US$ Mn) Forecast By Drug Class, 2022–2028 9.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013–2021 9.6.1. Oral 9.6.2. Injectable 9.7. Market Size (US$ Mn) Forecast By Route of Administration, 2022–2028 9.8. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013–2021 9.8.1. Anemia 9.8.2. Neutropenia 9.8.3. Thrombocytopenia 9.9. Market Size (US$ Mn) Forecast By Indication, 2022–2028 9.10. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2021 9.10.1. Hospital Pharmacies 9.10.2. Retail Pharmacies 9.10.3. Drug Stores 9.10.4. Online Pharmacies 9.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2022–2028 9.12. Market Attractiveness Analysis 9.12.1. By Country 9.12.2. By Drug Class 9.12.3. By Route of Administration 9.12.4. By Indication 9.12.5. By Distribution Channel 9.13. Drivers and Restraints – Impact Analysis 10. Latin America Radiation Induced Myelosuppression Treatment Market Analysis 2013–2021 and Forecast 2022–2028 10.1. Introduction 10.2. Historical Market Size (US$ Mn) By Country, 2013–2021 10.2.1. Brazil 10.2.2. Mexico 10.2.3. Argentina 10.2.4. Rest of Latin America 10.3. Market Size (US$ Mn) Forecast By Country, 2022–2028 10.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013–2021 10.4.1. Growth Factors 10.4.1.1. Granulocyte Colony-Stimulating Factor 10.4.1.2. Thrombopoietin Receptor Agonists 10.4.2. Erythropoietin-stimulating Agents 10.4.3. Thrombopoietic Agents 10.4.4. Iron supplementation 10.4.5. Others 10.5. Market Size (US$ Mn) Forecast By Drug Class, 2022–2028 10.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013–2021 10.6.1. Oral 10.6.2. Injectable 10.7. Market Size (US$ Mn) Forecast By Route of Administration, 2022–2028 10.8. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013–2021 10.8.1. Anemia 10.8.2. Neutropenia 10.8.3. Thrombocytopenia 10.9. Market Size (US$ Mn) Forecast By Indication, 2022–2028 10.10. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2021 10.10.1. Hospital Pharmacies 10.10.2. Retail Pharmacies 10.10.3. Drug Stores 10.10.4. Online Pharmacies 10.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2022–2028 10.12. Market Attractiveness Analysis 10.12.1. By Country 10.12.2. By Drug Class 10.12.3. By Route of Administration 10.12.4. By Indication 10.12.5. By Distribution Channel 10.13. Drivers and Restraints – Impact Analysis 11. Western Europe Radiation Induced Myelosuppression Treatment Market Analysis 2013–2021 and Forecast 2022–2028 11.1. Introduction 11.2. Historical Market Size (US$ Mn) By Country, 2013–2021 11.2.1. Germany 11.2.2. France 11.2.3. U.K. 11.2.4. Spain 11.2.5. Italy 11.2.6. Rest of Western Europe 11.3. Market Size (US$ Mn) Forecast By Country, 2022–2028 11.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013–2021 11.4.1. Growth Factors 11.4.1.1. Granulocyte Colony-Stimulating Factor 11.4.1.2. Thrombopoietin Receptor Agonists 11.4.2. Erythropoietin-stimulating Agents 11.4.3. Thrombopoietic Agents 11.4.4. Iron supplementation 11.4.5. Others 11.5. Market Size (US$ Mn) Forecast By Drug Class, 2022–2028 11.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013–2021 11.6.1. Oral 11.6.2. Injectable 11.7. Market Size (US$ Mn) Forecast By Route of Administration, 2022–2028 11.8. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013–2021 11.8.1. Anemia 11.8.2. Neutropenia 11.8.3. Thrombocytopenia 11.9. Market Size (US$ Mn) Forecast By Indication, 2022–2028 11.10. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2021 11.10.1. Hospital Pharmacies 11.10.2. Retail Pharmacies 11.10.3. Drug Stores 11.10.4. Online Pharmacies 11.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2022–2028 11.12. Market Attractiveness Analysis 11.12.1. By Country 11.12.2. By Drug Class 11.12.3. By Route of Administration 11.12.4. By Indication 11.12.5. By Distribution Channel 11.13. Drivers and Restraints – Impact Analysis 12. Eastern Europe Radiation Induced Myelosuppression Treatment Market Analysis 2013–2021 and Forecast 2022–2028 12.1. Introduction 12.2. Historical Market Size (US$ Mn) By Country, 2013–2021 12.2.1. Russia 12.2.2. Poland 12.2.3. Rest of Eastern Europe 12.3. Market Size (US$ Mn) Forecast By Country, 2022–2028 12.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013–2021 12.4.1. Growth Factors 12.4.1.1. Granulocyte Colony-Stimulating Factor 12.4.1.2. Thrombopoietin Receptor Agonists 12.4.2. Erythropoietin-stimulating Agents 12.4.3. Thrombopoietic Agents 12.4.4. Iron supplementation 12.4.5. Others 12.5. Market Size (US$ Mn) Forecast By Drug Class, 2022–2028 12.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013–2021 12.6.1. Oral 12.6.2. Injectable 12.7. Market Size (US$ Mn) Forecast By Route of Administration, 2022–2028 12.8. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013–2021 12.8.1. Anemia 12.8.2. Neutropenia 12.8.3. Thrombocytopenia 12.9. Market Size (US$ Mn) Forecast By Indication, 2022–2028 12.10. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2021 12.10.1. Hospital Pharmacies 12.10.2. Retail Pharmacies 12.10.3. Drug Stores 12.10.4. Online Pharmacies 12.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2022–2028 12.12. Market Attractiveness Analysis 12.12.1. By Country 12.12.2. By Drug Class 12.12.3. By Route of Administration 12.12.4. By Indication 12.12.5. By Distribution Channel 12.13. Drivers and Restraints – Impact Analysis 13. Asia Pacific excluding China (APEC) Radiation Induced Myelosuppression Treatment Market Analysis 2013–2021 and Forecast 2022–2028 13.1. Introduction 13.2. Historical Market Size (US$ Mn) By Country, 2013–2021 13.2.1. China 13.2.2. India 13.2.3. Australia and New Zealand 13.2.4. ASEAN 13.2.5. Rest of APAC 13.3. Market Size (US$ Mn) Forecast By Country, 2022–2028 13.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013–2021 13.4.1. Growth Factors 13.4.1.1. Granulocyte Colony-Stimulating Factor 13.4.1.2. Thrombopoietin Receptor Agonists 13.4.2. Erythropoietin-stimulating Agents 13.4.3. Thrombopoietic Agents 13.4.4. Iron supplementation 13.4.5. Others 13.5. Market Size (US$ Mn) Forecast By Drug Class, 2022–2028 13.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013–2021 13.6.1. Oral 13.6.2. Injectable 13.7. Market Size (US$ Mn) Forecast By Route of Administration, 2022–2028 13.8. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013–2021 13.8.1. Anemia 13.8.2. Neutropenia 13.8.3. Thrombocytopenia 13.9. Market Size (US$ Mn) Forecast By Indication, 2022–2028 13.10. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2021 13.10.1. Hospital Pharmacies 13.10.2. Retail Pharmacies 13.10.3. Drug Stores 13.10.4. Online Pharmacies 13.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2022–2028 13.12. Market Attractiveness Analysis 13.12.1. By Country 13.12.2. By Drug Class 13.12.3. By Route of Administration 13.12.4. By Indication 13.12.5. By Distribution Channel 13.13. Drivers and Restraints – Impact Analysis 14. Japan Radiation Induced Myelosuppression Treatment Market Analysis 2013–2021 and Forecast 2022–2028 14.1. Introduction 14.2. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013–2021 14.2.1. Growth Factors 14.2.1.1. Granulocyte Colony-Stimulating Factor 14.2.1.2. Thrombopoietin Receptor Agonists 14.2.2. Erythropoietin-stimulating Agents 14.2.3. Thrombopoietic Agents 14.2.4. Iron supplementation 14.2.5. Others 14.3. Market Size (US$ Mn) Forecast By Drug Class, 2022–2028 14.4. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013–2021 14.4.1. Oral 14.4.2. Injectable 14.5. Market Size (US$ Mn) Forecast By Route of Administration, 2022–2028 14.6. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013–2021 14.6.1. Anemia 14.6.2. Neutropenia 14.6.3. Thrombocytopenia 14.7. Market Size (US$ Mn) Forecast By Indication, 2022–2028 14.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2021 14.8.1. Hospital Pharmacies 14.8.2. Retail Pharmacies 14.8.3. Drug Stores 14.8.4. Online Pharmacies 14.9. Market Size (US$ Mn) Forecast By Distribution Channel, 2022–2028 14.10. Market Attractiveness Analysis 14.10.1. By Drug Class 14.10.2. By Route of Administration 14.10.3. By Indication 14.10.4. By Distribution Channel 14.11. Drivers and Restraints – Impact Analysis 15. MEA Radiation Induced Myelosuppression Treatment Market Analysis 2013–2021 and Forecast 2022–2028 15.1. Introduction 15.2. Historical Market Size (US$ Mn) By Country, 2013–2021 15.2.1. GCC Countries 15.2.2. South Africa 15.2.3. Rest of MEA 15.3. Market Size (US$ Mn) Forecast By Country, 2022–2028 15.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013–2021 15.4.1. Growth Factors 15.4.1.1. Granulocyte Colony-Stimulating Factor 15.4.1.2. Thrombopoietin Receptor Agonists 15.4.2. Erythropoietin-stimulating Agents 15.4.3. Thrombopoietic Agents 15.4.4. Iron supplementation 15.4.5. Others 15.5. Market Size (US$ Mn) Forecast By Drug Class, 2022–2028 15.6. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013–2021 15.6.1. Oral 15.6.2. Injectable 15.7. Market Size (US$ Mn) Forecast By Route of Administration, 2022–2028 15.8. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013–2021 15.8.1. Anemia 15.8.2. Neutropenia 15.8.3. Thrombocytopenia 15.9. Market Size (US$ Mn) Forecast By Indication, 2022–2028 15.10. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2021 15.10.1. Hospital Pharmacies 15.10.2. Retail Pharmacies 15.10.3. Drug Stores 15.10.4. Online Pharmacies 15.11. Market Size (US$ Mn) Forecast By Distribution Channel, 2022–2028 15.12. Market Attractiveness Analysis 15.12.1. By Country 15.12.2. By Drug Class 15.12.3. By Route of Administration 15.12.4. By Indication 15.12.5. By Distribution Channel 15.13. Drivers and Restraints – Impact Analysis 16. Forecast Factors: Relevance and Impact 17. Forecast Assumptions 18. Competition Analysis 18.1. Competition Dashboard 18.2. Market Structure Analysis 18.3. Company Deep Dive 18.3.1. Amgen Inc. 18.3.1.1. Overview 18.3.1.2. Product and Application Portfolio 18.3.1.3. Production Footprint 18.3.1.4. Sales Footprint 18.3.1.5. Channel Footprint 18.3.1.6. Strategy 18.3.1.6.1. Marketing Strategy 18.3.1.6.2. Product Strategy 18.3.1.6.3. Channel Strategy 18.3.2. Novartis AG 18.3.3. Teva Pharmaceutical Industries Ltd 18.3.4. Mylan N.V. 18.3.5. Pfizer Inc. 18.3.6. Janssen Global Services, LLC (Johnson & Johnson) 18.3.7. Partner Therapeutics, Inc. 18.3.8. Mission Pharmacal Company 18.3.9. Myelo Therapeutics GmbH 18.3.10. Pluristem Therapeutics Inc. 19. Global Radiation Induced Myelosuppression Treatment Market Analysis 2013–2021 and Forecast 2022–2028, By Region 19.1. Introduction / Key Findings 19.2. Historical Market Size (US$ Mn) Trend Analysis By Region, 2013–2021 19.2.1. North America 19.2.2. Latin America 19.2.3. Western Europe 19.2.4. Eastern Europe 19.2.5. Asia Pacific excluding Japan 19.2.6. Japan 19.2.7. Middle East and Africa 19.3. Market Size (US$ Mn) Forecast By Region, 2022–2028 19.4. Market Attractiveness Analysis By Region 20. Global Radiation Induced Myelosuppression Treatment Market Analysis 2013–2021 and Forecast 2022–2028, By Drug Class 20.1. Introduction 20.2. Historical Market Size (US$ Mn) Trend Analysis By Drug Class, 2013–2021 20.2.1. Growth Factors 20.2.1.1. Granulocyte Colony-Stimulating Factor 20.2.1.2. Thrombopoietin Receptor Agonists 20.2.2. Erythropoietin-stimulating Agents 20.2.3. Thrombopoietic Agents 20.2.4. Iron supplementation 20.2.5. Others 20.3. Market Size (US$ Mn) Forecast By Drug Class, 2022–2028 20.4. Market Attractiveness Analysis By Drug Class 21. Global Radiation Induced Myelosuppression Treatment Market Analysis 2013–2021 and Forecast 2022–2028, By Route of Administration 21.1. Introduction 21.2. Historical Market Size (US$ Mn) Trend Analysis By Route of Administration, 2013–2021 21.2.1. Oral 21.2.2. Injectable 21.3. Market Size (US$ Mn) Forecast By Route of Administration, 2022–2028 21.4. Market Attractiveness Analysis By Route of Administration 22. Global Radiation Induced Myelosuppression Treatment Market Analysis 2013–2021 and Forecast 2022–2028, By Indication 22.1. Introduction 22.2. Historical Market Size (US$ Mn) Trend Analysis By Indication, 2013–2021 22.2.1. Anemia 22.2.2. Neutropenia 22.2.3. Thrombocytopenia 22.3. Market Size (US$ Mn) Forecast By Indication, 2022–2028 22.4. Market Attractiveness Analysis By Indication 23. Global Radiation Induced Myelosuppression Treatment Market Analysis 2013–2021 and Forecast 2022–2028, By Distribution Channel 23.1. Introduction 23.2. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2021 23.2.1. Hospital Pharmacies 23.2.2. Retail Pharmacies 23.2.3. Drug Stores 23.2.4. Online Pharmacies 23.3. Market Size (US$ Mn) Forecast By Distribution Channel, 2022–2028 23.4. Market Attractiveness Analysis By Distribution Channel 24. Research Methodology
Healthcare
March 2022
REP-GB-1364
July 2022
211 pages
Healthcare
January 2022
REP-GB-8116
July 2022
207 pages
Explore Healthcare Insights
View Reports
Radiation-Induced Myelosuppression Treatment Market
